COMPOUND PROFILE / PEPTIDES & ANALOGUES
FOXO4-DRI.
Research draftFOXO4-DRI is an experimental senolytic peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
FOXO4-DRI is an experimental senolytic peptide.
Mechanism
It is designed to disrupt FOXO4-p53 interactions and promote death of selected senescent cells.
Human research
A therapeutic human evidence base was not established.
Preclinical & other research
Cell and aged-mouse studies examined senescence-related endpoints; human-cell experiments are still preclinical.
Safety & unknowns
Selective cell removal and longer-term tissue effects are not characterised sufficiently in people.
Regulatory status
Preclinical research compound, not an established rejuvenation treatment.
Reported use & evidence
The supplied FOXO4-DRI profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.